Results 1 to 10 of about 93,898 (384)

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study. [PDF]

J Clin Med
Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce.
Pini L, Bagnasco D, Beghè B, Braido F, Cameli P, Caminati M, Caruso C, Crimi C, Guarnieri G, Latorre M, Menzella F, Micheletto C, Vianello A, Visca D, Bondi B, El Masri Y, Giordani J, Mastrototaro A, Maule M, Pini A, Piras S, Zappa M, Senna G, Spanevello A, Paggiaro P, Blasi F, Canonica GW, On Behalf Of The Sani Study Group.   +27 more
europepmc   +4 more sources

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma [PDF]

Biomedicines, 2022
Severe asthma is characterized by different endotypes driven by complex pathologic mechanisms. In most patients with both allergic and non-allergic asthma, predominant eosinophilic airway inflammation is present.
Alessandro Vatrella, Angelantonio Maglio, Corrado Pelaia, Luigi Ciampo, Giulia Pelaia, Carolina Vitale   +5 more
doaj   +2 more sources

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

Frontiers in Immunology, 2023
IntroductionClinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma ...
Ian Pavord, Frances Gardiner, Liam G. Heaney, Christian Domingo, Robert G. Price, Alison Pullan, John Oppenheimer, Guy Brusselle, Hiroyuki Nagase, Geoffrey Chupp, Emilio Pizzichini, Emilio Pizzichini, David Bañas-Conejero, Peter Howarth   +13 more
doaj   +2 more sources

Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study

Therapeutic Advances in Respiratory Disease, 2021
Background: Severe eosinophilic asthma is frequently associated to chronic rhinosinusitis and nasal polyposis (CRSwNP) that contribute to poor asthma control.
Aikaterini Detoraki, Eugenio Tremante, Maria D’Amato, Cecilia Calabrese, Claudia Casella, Mauro Maniscalco, Remo Poto, Raffaele Brancaccio, Matilde Boccia, Maria Martino, Clara Imperatore, Giuseppe Spadaro   +11 more
doaj   +2 more sources

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis

Frontiers in Allergy, 2022
Background Severe eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation.
Maria D’Amato, Francesco Menzella, Elena Altieri, Elena Bargagli, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Fabiano Di Marco, Elide A. Pastorello, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Gianenrico Senna, Alessandra Vultaggio, Alessandra Ori, Lucia Simoni, Silvia Boarino, Gianfranco Vitiello, Maria Aliani, Stefano Del Giacco   +24 more
openalex   +2 more sources

Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study

Journal of Asthma and Allergy, 2022
Ismael García-Moguel,1,2 Ana Rosado,3 Aída Gómez-Cardeñosa,4,5 Mar Gandolfo-Cano,6,7 Teresa Robledo Echarren,8 Maria del Mar Moro Moro,9 Mª del Mar Reaño Martos,10 Rafael Pineda-Pineda,11 Marcela Valverde-Monge,4,5 Cristina Martin-Arriscado Arroba,12 ...
García-Moguel I, Rosado A, Gómez-Cardeñosa A, Gandolfo-Cano M, Robledo Echarren T, Moro Moro MDM, Reaño Martos MDM, Pineda-Pineda R, Valverde-Monge M, Martin-Arriscado Arroba C, Domínguez-Ortega J   +10 more
doaj   +2 more sources

Use of FeNO to Predict Anti-IL-5 and IL-5R Biologics Efficacy in a Real-World Cohort of Adults with Severe Eosinophilic Asthma

Journal of Asthma, 2022
Introduction Severe eosinophilic asthma (SEA) is associated with multiple exacerbations. Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to be correlated with the risk of exacerbations.
Charlotte Ménigoz, S. Dirou, Arnaud Chambellan, Dorian Hassoun, Antoine Moui, A. Magnan, F.–X. Blanc   +6 more
openalex   +2 more sources

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. [PDF]

Eur Respir J
Graphical abstract In this large, real-world programme, patients with severe eosinophilic asthma treated with benralizumab had substantial improvements in clinical outcomes, irrespective of previous biologic use and key clinical characteristics important
Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, Shavit A, Arbetter D, Katial R, Rabe APJ, Garcia Gil E, Pardal M, Nuevo J, Watt M, Boarino S, Kayaniyil S, Chaves Loureiro C, Padilla-Galo A, Nair P.   +18 more
europepmc   +2 more sources

Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use

Therapeutics and Clinical Risk Management, 2018
Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai &ndash ...
Maselli DJ, Rogers L, Peters JI
doaj   +3 more sources

Efficacy and safety of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis. [PDF]

J Thorac Dis
Li Y, Li J, Yang H, Wu L.
europepmc   +2 more sources